Shunyi Lu

Shunyi Lu

Auto-generated profile, based on publicly available information

Shunyi Lu

Department of Orthopedic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SLShunyi Lu
Shunyi Lu
JCJie Cao
Jie Cao
ZSZhuorun Song
Zhuorun Song
FGFei Gong
Fei Gong
PYPeng Yang
Peng Yang
HYHuilin Yang
Huilin Yang
The treatment of osteoporosis and related bone defects remains challenging. This study identifies pyroptosis-driven inflammation as a key disruptor of bone homeostasis. To address this, we develop a magnesium-gelatin composite microsphere scaffold (GelMa/Mg/DMF MS) that exploit pyroptosis blockade and hydrogen-mediated inflammation regulation for osteoporosis treatment. This porous microsphere scaffold is implanted into bone defects to achieve the sustained release of hydrogen gas, magnesium ions (Mg2+), and dimethyl fumarate (DMF). DMF act by activating the nuclear factor erythroid-related factor 2 to prevent osteoblast pyroptosis, and combine with the antioxidant effects of hydrogen, effectively remodel the inflammatory microenvironment and create favorable conditions for the restoration of bone homeostasis. Mg2+ further expedite bone tissue repair. These results demonstrate that the GelMa/Mg/DMF MS effectively reverse inflammatory microenvironments both in vivo and in vitro, resulting in significant tissue repair. These results suggest the combination of hydrogen therapy and pyroptosis blockade as a potential therapeutic strategy.

25 April 2023 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
BHBinfeng He
Binfeng He
SLShunyi Lu
Shunyi Lu
YYYa Yuan
Ya Yuan
LHLei Huang
Lei Huang
MBMengxuan Bian
Mengxuan Bian
JZJian Zhang
Jian Zhang
Background. Peripheral nerve injury (PNI) is one of the most debilitating injuries, but therapies for PNI are still far from satisfactory. Pyroptosis, a recently identified form of cell death, has been demonstrated to participate in different diseases. However, the role of pyroptosis of Schwann cells in PNI remains unclear. Methods. We established a rat PNI model, and western blotting, transmission electron microscopy, and immunofluorescence staining were used to confirm pyroptosis of Schwann cells in PNI in vivo. In vitro, pyroptosis of Schwann cells was induced by lipopolysaccharides (LPS)+adenosine triphosphate disodium (ATP). An irreversible inhibitor of pyroptosis, acetyl (Ac)-Tyr-Val-Ala-Asp-chloromethyl ketone (Ac-YVAD-cmk), was used to attenuate Schwann cell pyroptosis. Moreover, the influence of pyroptotic Schwann cells on the function of dorsal root ganglion neurons (DRGns) was analyzed by a coculture system. Finally, the rat PNI model was intraperitoneally treated with Ac-YVAD-cmk to observe the effect of pyroptosis on nerve regeneration and motor function. Results. Schwann cell pyroptosis was notably observed in the injured sciatic nerve. LPS+ATP treatment effectively induced Schwann cell pyroptosis, which was largely attenuated by Ac-YVAD-cmk. Additionally, pyroptotic Schwann cells inhibited the function of DRGns by secreting inflammatory factors. A decrease in pyroptosis in Schwann cells promoted regeneration of the sciatic nerve and recovery of motor function in rats. Conclusion. Given the role of Schwann cell pyroptosis in PNI progression, inhibition of Schwann cell pyroptosis might be a potential therapeutic strategy for PNI in the future.

25 May 2024 in Materials Today Bio
Verified
Journal Article
Open access
LHLei Huang
Lei Huang
PCPeihao Cai
Peihao Cai
MBMengxuan Bian
Mengxuan Bian
JYJieqin Yu
Jieqin Yu
Lan XiaoLan Xiao
Lan Xiao
JZJian Zhang
Jian Zhang
Osteoporosis (OP) can result in slower bone regeneration than the normal condition due to the imbalance between osteogenesis and osteoclastogenesis, making osteoporotic bone defects healing a significant clinical challenge. Calcium phosphate cement (CPC) is a promising bone substitute material due to its good osteoinductive activity, however, the drawbacks such as fragility, slow degradation rate and incapability to control bone loss restrict its application in osteoporotic bone defects treatment. Currently, we developed the PLGA electrospun nanofiber sheets to carry alendronate (ALN) and magnesium oxide nanoparticle (nMgO) into CPC, therefore, to obtain a high-strength bone cement (C/AM-PL/C). The C/AM-PL/C bone cement had high mechanical strength, anti-washout ability, good injection performance and drug sustained release capacity. More importantly, the C/AM-PL/C cement promoted the osteogenic differentiation of bone marrow mesenchymal stem cells and neovascularization via the release of Mg2+ (from nMgO) and Ca2+ (during the degradation of CPC), and inhibited osteoclastogenesis via the release of ALN in vitro. Moreover, the injection of C/AM-PL/C cement significantly improved bone healing in an OP model with femur condyle defects in vivo. Altogether, the injectable C/AM-PL/C cement could facilitate osteoporotic bone regeneration, demonstrating its capacity as a promising candidate for treatment of osteoporotic bone defects.

26 April 2025 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
XXXingdong Xiang
Xingdong Xiang
LHLei Huang
Lei Huang
WLWenchen Luo
Wenchen Luo
LQLieyang Qin
Lieyang Qin
MBMengxuan Bian
Mengxuan Bian
TFTengfei Fu
Tengfei Fu
Stroke-related sarcopenia can result in muscle mass loss and muscle fibers abnormality, significantly affecting muscle function. The clinical management of stroke-related sarcopenia still requires further research and investigation. This study aims to explore a promising therapy to restore muscle function and promote muscle regeneration in stroke-related sarcopenia, providing a new theory for stroke-related sarcopenia treatment. Stroke-related sarcopenia rat model was established by using permanent middle cerebral artery occlusion (pMCAO) rat and treated with neuromuscular electrical stimulation (NMES). Electrical stimulation (ES) treatment in vitro was mimicked to test the effect of NMES on muscle regeneration in rat skeletal muscle satellite cells (MuSCs). Catwalk, H&E and Masson's trichrome staining, immunofluorescence, transcriptomic analysis, transmission electron microscopy, MuSCs transfection, autophagy flux detection, quantitative real-time PCR analysis, Co-Immunoprecipitation and Western Blot were used to investigate the role of NMES and its mechanism in stroke-related sarcopenia in vivo. After NMES treatment, muscle mass and myogenic differentiation were significantly increased in stroke-related sarcopenia rats. The NMES group had more stable gait, neater footprints, higher muscle wet weight, more voluminous morphology and more regenerated muscle fibers. Additionally, ES treatment induced myogenic differentiation in rat MuSCs in vitro. Transcriptomic analysis also showed that "AMPK signaling pathway" was enriched and genes upregulated in ES-treated cells, revealing ES treatment could activate the autophagy in an AMPK-ULK1-dependent mechanism in MuSCs. Besides, it was also founded that infusion of AMPK or ULK1 inhibitor, knockdown of AMPK or ULK1 in MuSCs could block the effect of myotube formation of ES. NMES not only restores muscle function but also enhances myogenic activity and muscle regeneration via AMPK-ULK1 autophagy in stroke-related sarcopenia rats. Our study provides a promising strategy for the treatment of stroke-related sarcopenia. This study first demonstrates that NMES alleviates stroke-related sarcopenia by promoting MuSCs differentiation through AMPK-ULK1-autophagy axis. The findings reveal a novel therapeutic mechanism, suggesting that NMES can restore muscle function and enhance regeneration in stroke patients. By combining NMES with MuSCs-based therapies, this approach offers a promising strategy for clinical rehabilitation, potentially improving muscle mass and function in stroke survivors. The translational potential lies in its applicability to non-invasive, cost-effective treatments for sarcopenia, enhancing patients' quality of life.

12 May 2025 in Regenerative Medicine Reports
Verified
Journal Article
Open access
LHLei Huang
Lei Huang
JWJiayi Wang
Jiayi Wang
JXJin Xu
Jin Xu
MBMengxuan Bian
Mengxuan Bian
JWJianjie Wang
Jianjie Wang
SLShunyi Lu
Shunyi Lu
Bone healing is a complex multifactor and diverse physiological process. In terms of osteogenic differentiation, different types of regulated cell death, such as ferroptosis, play key roles in the bone microenvironment. Ferroptosis is a new type of regulated cell death discovered in 2012. It is characterized by lipid peroxidation and iron-dependent accumulation, which are closely related to various clinical challenges. In recent years, an increasing number of studies have indicated a strong potential relationship between ferroptosis and different orthopedic diseases, including osteoporosis, osteopenia and osteoarthritis. Hence, an in-depth investigation of the relationship between ferroptosis and bone metabolism is highly important for the treatment of orthopedic diseases. Moreover, ferroptosis is also accompanied by morphological changes in mitochondria, such as increased membrane density and shrunken mitochondria, which have been detected in osteoblasts, bone marrow stem mesenchymal cells and osteoclasts. The inhibition of ferroptosis can reduce mitochondrial damage, alleviate oxidative stress and promote bone regeneration. This article reviews the mechanism of ferroptosis from the aspects of iron overload and the regulation of ferroptosis-related pathways, as well as their effects on bone regeneration. Increasing evidence has shown that bone defect healing and bone regeneration processes are closely related to abnormal iron metabolism. Inhibiting ferroptosis in bone marrow mesenchymal stem cells or osteoblasts can effectively improve the bone healing rate and promote bone regeneration progression. We discuss the detailed mechanism of ferroptosis and summarize the current research on ferroptosis and bone disease treatment.

25 June 2025 in Regenerative Medicine Reports
Verified
Journal Article
Open access
YZYongxin Zhang
Yongxin Zhang
LHLei Huang
Lei Huang
MLMangui Li
Mangui Li
PYPeng Yang
Peng Yang
LCLiming Cheng
Liming Cheng
JZJian Zhang
Jian Zhang
JOURNAL/rmrep/04.03/02273995-202512000-00002/figure1/v/2026-04-22T111838Z/r/image-tiff The relationship between obesity and bone health remains controversial, with extensive studies suggesting associations; however, the precise nature of this relationship remains uncertain. Relative fat mass (RFM) is an innovative obesity metric that provides a more precise evaluation of body fat distribution than conventional methods, but its implications for skeletal health remain unexplored. This study aimed to explore the relationship between RFM and lumbar bone mineral density (BMD) in adults from 2011–2018. Weighted multivariate logistic regression, subgroup analysis, and interaction tests were employed to examine the relationship between RFM and lumbar BMD, utilizing data derived from the 2011–2018 National Health and Nutrition Examination Survey. This study included a total of 11,410 participants. Weighted multiple linear regression analysis revealed a significant negative correlation between RFM and lumbar BMD among adults aged 20–59 years. This negative correlation persisted even when RFM was analyzed by quartiles, with individuals in the highest RFM quartile exhibiting lumbar BMD levels 0.046 g/cm 2 lower than those in the lowest quartile. However, the results of the subgroup analysis suggested that this negative association was abolished in individuals with diabetes, hypertension, or chronic kidney disease but was not significantly influenced by factors such as sex and race. Our findings indicate a significant negative correlation between RFM and lumbar BMD in US adults aged 20–59 years, with notable attenuation in specific clinical populations, offering fresh perspectives and research targets for clinical analysis.